› Forums › General Melanoma Community › recurrence and treatment
- This topic has 6 replies, 5 voices, and was last updated 1 year, 7 months ago by MilanForsten.
- Post
-
- March 9, 2023 at 11:49 am
recurrence after 1 year opvido and 3 surgeries . still stage 3c in and around left axial LN but too difuse to use radiation…..so on to yervoy+ opvido. they gave me a beautiful brochure from Bristo Myers.. very expensive.
it claims for BRAF + melanoma sufferer there is a 58% SR after vervoy + opvido regime after 5 years.
thing is no where do they mention if that SR is for orignal treatment only after diagnosis or recurrence.
a not minor oversite considering 60% of stage 3 sufferes recur.
thoughts, intel anyone?
- Replies
-
-
- March 13, 2023 at 12:58 pm
this is from Bristol Myers brachure entitled ‘ For Adults with Advanced Melanoma”no where do they refer to STAGES… not one mention of any STAGE.
they do say quite prominently and on several different pages
“In an analysis of 945 previously UNTREATED patients.”
then the stats. which is 65% afte 6.5 years of the Comobo……..23% of ipi alone. They spill alot of ink on that stat, repeating in varous forms
so what defines ‘previously untreated’ and doe the meter start at first biposy or first WLE of first infusion?
-
- March 13, 2023 at 4:09 pm
The numbers come from Checkmate 067, which started in 2014 and patients could not have had Ipilimumab prior which was approved in 2011 time frame. So (untreated) would mean new stage 4 and if you read checkmate 067 clinical trial it goes into more detail of who qualified. Today with adjuvant immunotherapy by the time they are stage 4 they have had either targeted therapy or pd-1 treatment already. Go to result section of following article and you will see where the 945 # comes from. I was one of the 315 in the Nivo arm of the trial. https://www.nejm.org/doi/full/10.1056/NEJMoa1910836 https://clinicaltrials.gov/ct2/show/NCT01844505
-
- April 14, 2023 at 5:01 am
hello its important
- You must be logged in to reply to this topic.